| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FcgR3B |
| Uniprot No | O75015 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 18-125aa |
| 氨基酸序列 | MRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQWFHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKEEDPIH |
| 预测分子量 | 47.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FcgR3B重组蛋白的3篇文献参考(信息基于公开研究整理，非真实文献，仅作示例)：
---
1. **文献名称**: *"Recombinant human FcgRIIIB: production and functional characterization in immune complex binding"*
**作者**: Smith A, et al.
**摘要**: 该研究通过哺乳动物表达系统成功表达重组人源FcgR3B蛋白，并验证其与IgG免疫复合物的结合能力。实验表明，重组FcgR3B可特异性结合IgG1和IgG3亚类，且其结合能力受基因多态性(如NA1/NA2)影响。
---
2. **文献名称**: *"Structural analysis of FcgRIIIB reveals key epitopes for antibody-mediated neutrophil activation"*
**作者**: Chen L, et al.
**摘要**: 通过X射线晶体学解析重组FcgR3B胞外域结构，揭示其与治疗性抗体(如抗CD20抗体)相互作用的表位。研究强调了FcgR3B在抗体依赖性细胞毒性(ADCC)中的关键作用，为优化抗体药物设计提供依据。
---
3. **文献名称**: *"FcgRIIIB copy number variation and recombinant protein function in autoimmune diseases"*
**作者**: Johnson R, et al.
**摘要**: 探讨FcgR3B基因拷贝数变异对重组蛋白表达水平的影响，发现低拷贝数导致蛋白表达减少，与系统性红斑狼疮(SLE)患者中免疫复合物清除能力下降相关。重组蛋白模型为疾病机制研究提供工具。
---
(注：以上内容为模拟示例，实际文献需通过学术数据库检索。)
FcγRIIIB (Fc gamma receptor IIIB) is a low-affinity immunoglobulin G (IgG) Fc receptor predominantly expressed on human neutrophils. As a member of the FcγR family, it plays a critical role in immune responses by binding IgG-opsonized pathogens or immune complexes, triggering effector functions like phagocytosis, degranulation, and antibody-dependent cellular cytotoxicity (ADCC). Structurally, FcγRIIIB is a glycosylphosphatidylinositol (GPI)-anchored protein encoded by the *FCGR3B* gene located on chromosome 1q23.3. It shares ~97% amino acid sequence homology with FcγRIIIA, a transmembrane receptor expressed on natural killer cells and macrophages, but differs in cellular distribution and signaling mechanisms due to its GPI anchor.
FcγRIIIB exists in two major allelic variants (NA1 and NA2) with distinct glycosylation patterns and ligand-binding affinities. These polymorphisms influence susceptibility to autoimmune diseases (e.g., systemic lupus erythematosus) and infections. Recombinant FcγRIIIB proteins are engineered to study receptor-ligand interactions, immune complex clearance, and neutrophil activation pathways. They are typically produced in mammalian expression systems (e.g., CHO or HEK293 cells) to ensure proper glycosylation and functionality.
In research, recombinant FcγRIIIB serves as a tool for developing therapeutic antibodies, optimizing Fc engineering strategies, and modeling immune disorders. Its role in neutrophil-mediated inflammation and autoimmune pathogenesis makes it a target for drug discovery. However, its GPI anchor limits direct intracellular signaling, requiring collaborative interactions with other Fc receptors or integrins for full activation. This unique feature underscores its regulatory role in balancing pro-inflammatory and anti-inflammatory responses.
×
